PortViewPortView
RenovoRx logo

RenovoRx (RNXT) Stock Analysis

NASDAQHealthcareBiotechnology

$2.38+12.56%
1-year price historyRange $0.73 – $2.40
52-week range$2.38
$0.70$2.48

What RenovoRx does

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.

Key metrics

Market cap
$107.00M
P/E (TTM)
-8.19
EPS (TTM)
$-0.29
Beta
0.99
Dividend yield
0.00%
Revenue / share
$0.04
50-day avg
$1.10
200-day avg
$0.97
52-week high
$2.48
52-week low
$0.70
CEO
Shaun R. Bagai

ETFs linked to RNXT

Broad-market and Healthcare sector ETFs an investor holding RenovoRx is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how RNXT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze RNXT in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for RenovoRx?
RenovoRx trades under the ticker RNXT on NASDAQ.
Which exchange is RNXT listed on?
RNXT is listed on NASDAQ.
What sector does RenovoRx operate in?
RenovoRx is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze RNXT in a portfolio?
PortView shows RNXT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.